{"id":"NCT02808819","sponsor":"AstraZeneca","briefTitle":"A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist","officialTitle":"A Multicenter, Open-label, Safety Extension Study With Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-30","primaryCompletion":"2020-06-18","completion":"2020-06-18","firstPosted":"2016-06-22","resultsPosted":"2021-04-13","lastUpdate":"2021-04-13"},"enrollment":447,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]}],"arms":[{"label":"Benralizumab Arm A","type":"OTHER"},{"label":"Benralizumab Arm B","type":"OTHER"}],"summary":"The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).","primaryOutcome":{"measure":"Change From Baseline in Basophils, Full Analysis Set","timeFrame":"From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.","effectByArm":[{"arm":"Benra 30 mg q.4 Weeks","deltaMin":0.014,"sd":0.0229},{"arm":"Benra 30 mg q.8 Weeks","deltaMin":0.012,"sd":0.0243},{"arm":"Total","deltaMin":0.013,"sd":0.0236}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":178,"countries":["United States","Argentina","Australia","Bulgaria","Canada","Chile","Czechia","France","Germany","Poland","Russia","Spain","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00037&amp;attachmentIdentifier=c52ffe9a-53b4-40d3-935b-1b8ecf80bc07&amp;fileName=d3250c00037-revised-csp-2-redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00037&amp;attachmentIdentifier=d7b2554d-b014-4ffa-adec-c930fc06f4f5&amp;fileName=d3250c00037-sap-ed-2-redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":220},"commonTop":["Nasopharyngitis","Headache","Viral upper respiratory tract infection","Bronchitis","Hypertension"]}}